Navigation Links
Clinical benefit of multiple sclerosis drug discovered at Rush University Medical Center
Date:4/5/2010

A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.

The drug, called dalfampridine, is the first therapy for multiple sclerosis that can be taken orally. It is also the first FDA-approved therapy to treat impaired walking, a debilitating symptom of the disease limiting patients' independence and ability to accomplish the most basic tasks of daily living. While other multiple sclerosis drugs work by decreasing the inflammation that causes damage to the central nervous system, dalfampridine is designed to allow conduction of nerve impulses despite the damage.

Research that led to the discovery of dalfampridine's therapeutic value dates back to the 1960s, when Dr. Floyd Davis, then a neurologist in training and later a physician at Rush, became intrigued by an unusual clinical observation: many multiple sclerosis patients fare better when their body temperature is slightly lowered, even by just two- or three-tenths of a degree.

"In multiple sclerosis, the protective myelin sheath that wraps around nerve fibers in the brain and spinal cord is damaged, essentially causing a short circuit," said Davis, who is now retired. "Somehow, lower body temperature enabled the electrical pulse to continue its travel along the nerve fibers. I was completely transfixed by the significance of that fact."

It was important because it showed "that the damaged nerve fibers were not doomed, as previously believed," said Dr. Dusan Stefoski, director of the Rush Multiple Sclerosis Center, who teamed up with Davis in 1978, shortly after completing neurology training at Rush.

Davis launched a series of laboratory studies to understand the mechanism that explained the noticeable improvement in symptoms.

He then looked for a compound that could mimic some of the effects of lower bo
'/>"/>

Contact: Sharon Butler
Sharon_Butler@rush.edu
312-942-7816
Rush University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
2. FDA Issues Guidance to Help Streamline Medical Device Clinical Trials
3. Clinical course of subepithelial lesions
4. Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial
5. NHLBI funds preclinical tests on devices for infants and children with congenital heart defects
6. Medpedia Launches New Clinical Trial Platform
7. Most Antidepressants Miss Key Target of Clinical Depression
8. Banner Health Systems Adopts Quantros Regulatory Reporting Management (RRM) to Manage Clinical Quality and Performance Data and Support Improvements in Quality of Care
9. Health Systems, Hospitals and Universities Nationwide Chose Epocrates in 2009 for Trusted Point-of-Care Clinical Information
10. European Cancer Organization supports a revision of the EU Clinical Trials Directive
11. Roche and Catalyst Resources Team to Explore RIA Healthcare Collaboration Solutions for Enhanced Clinical Diagnosis and Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Key West Health & Beauty’s ( http://www.keywesthealthandbeauty.com ... anticipated study results of the 12 best and worst ... accompanying infographic on their website. It appears that the ... impact on the skin and contribute to many unwanted ... asked how they determined the results, founder and skin ...
(Date:8/22/2014)... Medical Oncology (ESMO), the leading pan-European organisation representing ... three outstanding individuals receiving the Society,s esteemed annual ... Bokemeyer, Heikki Joensuu and Peter Boyle on the ... Madrid, Spain. , Carsten Bokemeyer will receive the ... transition of cancer discovery into real benefit at ...
(Date:8/22/2014)... in Sweden provides insight on how the brain processes ... different sources and sides of the body, in order ... are presented in the journal Neuron , show ... various types of sensory information, with specialised functional roles ... the main input structure in the basal ganglia, and ...
(Date:8/22/2014)... Oncology (ESMO), the leading pan-European organisation representing medical ... outstanding individuals receiving the Society,s esteemed annual awards. ... Heikki Joensuu and Peter Boyle on the occasion ... Spain. , Carsten Bokemeyer will receive the ESMO ... of cancer discovery into real benefit at patient ...
(Date:8/22/2014)... air in American cities is getting safer to breathe, ... progress has been made in reducing levels of harmful ... said in a news release. Since 1990, there ... from human sources such as coal-fired plants, a 66 ... in lead, which harms brain development in children. ...
Breaking Medicine News(10 mins):Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:The striatum acts as hub for multisensory integration 2Health News:ESMO honours outstanding oncology professionals 2Health News:ESMO honours outstanding oncology professionals 3Health News:Air in U.S. Cities Getting Cleaner, EPA Says 2
... Consuming Vitamin B ,With the rising costs of healthcare, ... a cheap and effective way of warding off health ... and heart disease//. ,Research in the past ... acid known to be a marker of cardiovascular disease ...
... bald mice to get fur on the body, says a ... C. Thompson and colleagues at Johns Hopkins University School// of ... encodes a protein that is essential for hair follicle regeneration. ... Hairless gene, hair growth is initially normal. But once hair ...
... Sometimes the answers to complex problems lies at hand but ... case with a new anti obesity drug//. A weight control ... monitor body fat content may yield new approaches for treating ... further suggest that particular variants of the protein SH2-B might ...
... is considering whether to temporarily ban the Environmental Protection ... a pesticide should be marketed//. Lawmakers on Capitol Hill ... moratorium on the conduct and use of studies that ... conducted by companies seeking to have their pesticides approved ...
... Manipur have hope at hand with an international aid ... care and treatment//.,The Nobel prize-winning Medicines Sans Frontieres (MSF) ... understanding with the Manipur government to provide healthcare services, ... Dutch chapter of the MSF would be involved in ...
... some people vulnerable to suffer from the dreaded disease ... diagnose the risk//. ,According to the most complete ... the researchers from Vanderbilt University in Nashville, Tennessee at ... in San Diego, a cluster of genes on chromosome ...
Cached Medicine News:Health News:An Answer To Obesity: Weight Control Protein 2Health News:US Senate Votes against Testing of Pesticide on Humans 2Health News:Specialized Clinics For Manipur's AIDS Patients 2
(Date:8/22/2014)... Aug. 22, 2014   Zacks Equity Research highlights Epizyme ... the Day and Panera (Nasdaq: PNRA - Free Report ) ... provides analysis on Amicus Therapeutics (Nasdaq: FOLD - Free Report ... (Nasdaq: SHPG - Free Report ). Here is ... of the Day : The biotech bull market ...
(Date:8/22/2014)... Research and Markets has announced the addition ... Report 2014" report to their offering. ... 2014 is a professional and in-depth study on the ... a focus on the Chinese situation. The report ... classifications, applications and industry chain structure. The particulate respirators ...
(Date:8/22/2014)... , Cali ., Aug. 22, 2014 ... Papillomavirus Conference shows that a therapy being developed by Hera ... two that cause 70 percent of all cervical cancer. ... blocked the replication of HPV-16, HPV-18 and HPV-11 cells, according ... Broker , Ph.D., who presented the findings at the ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Global and Chinese Particulate Respirators Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... DIEGO, Jan. 31, 2011 Volcano Corporation (Nasdaq: ... of Massachusetts has issued a decision that ruled in ... Inc., and against LightLab Imaging, Inc., on all of ... 11-page decision also rejected LightLab,s request for injunctive relief. ...
... its continuing partnerships with Brazilian public health authorities and ... Mr. Nelson dos Santos as interim vice president of ... nonprofit organization whose mission is to improve the health ... programs that help ensure the quality, safety and benefit ...
Cached Medicine Technology:Massachusetts Court Rules in Favor of Volcano and Against St. Jude Medical Subsidiary in Trade Secrets Case 2New Interim Leadership for USP-Brazil 2
The Olympus continuous flow cystoscope was especially designed for laser treatment of the prostate and for collagen injection....
... Prostatron® System uses Cooled ... -TUMT®) to deliver precisely ... heat and destroy hyperplastic ... unique cooling mechanism simultaneously ...
... provides diagnostic testing in an easily ... a PCMCIA card,providing you diagnostic testing ... full-featured and performs all the,measurements performed ... to Office,Medic software for real-time data ...
... is a simple "1, 2, 3 ... compact with a streamline design It ... 13.5 lbs. It rapidly charges to ... full summary pre- & post-event documentation ...
Medicine Products: